Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer Clinical Trial

Official title:

Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02352831
• Other study ID #: 201503074
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: August 31, 2015
• Est. completion date: October 19, 2018

Study information

• Verified date: August 2019
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine. The goal of the second part of the study is to look at how participants respond to treatment with tosedostat and capecitabine.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: October 19, 2018
• Est. primary completion date: October 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically proven metastatic or inoperable pancreatic adenocarcinoma.

• Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >10 mm with CT scan or MRI, as >20 mm by chest x-ray, or >10 mm with calipers by clinical exam.

• Must have progressed on, been intolerant to, or refused gemcitabine-based therapy.

• At least 18 years of age.

• ECOG performance status = 2

• Normal bone marrow and organ function as defined below:

• Absolute neutrophil count = 1,000/mcl

• Platelets = 100,000/mcl

• Total bilirubin = 2.0 mg/dL

• Creatinine = 2.0 mg/dL

• AST or ALT =2.5 IULN (=5X IULN if liver metastases are present)

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Chemotherapy < 2 weeks prior to the first planned dose of study treatment.

• Radiotherapy < 3 weeks prior to the first planned dose of study treatment.

• A history of other malignancy = 2 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.

• Currently receiving any other investigational agents.

• Known brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to tosedostat or capecitabine or other agents used in the study.

• Previous treatment with any aminopeptidase inhibitor.

• Previous exposure to either 5-FU or capecitabine at a systemic dose except for use in concurrent chemoradiation.

• Known dihydropyrimidine dehydrogenase (DPD) deficiency or severe renal impairment (creatinine clearance < 30 mL/min by Cockcroft-Gault formula), as this would preclude use of capecitabine.

• Significant cardiovascular disease defined as:

• Myocardial infarction within 6 months of screening.

• Unstable angina pectoris

• Uncontrolled or clinically significant arrhythmia Grade = 2

• LVEF = below institutional limits at screening

• Congestive heart failure NYHA class III or IV

• Presence of clinically significant valvular heart disease

• Baseline troponin I or T > IULN and b-type natriuretic peptide > IULN.

• Prior exposure to cardiotoxic agent, such as anthracyclines, within 3 months of enrollment.

• Patient must have a QTc interval on ECG = 0.48 seconds by Bazett's calculation at screening.

• Patient may not be taking any drugs that prolong the QT/QTc interval. If patient is on any of these drugs, patient may enroll in the study if the drugs can be discontinued for at least 5 half-lives prior to the first dose of tosedostat and capecitabine.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant and/or breastfeeding. Patients that are of childbearing age must have a negative pregnancy test at screening and agree on using contraception during the duration of the study.

• Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with tosedostat or capecitabine. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Related Conditions & MeSH terms

• Adenocarcinoma
• Cancer of Pancreas
• Cancer of the Pancreas
• Pancreas Cancer
• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Tosedostat

• Capecitabine

Procedure:
• Fresh tissue biopsy
Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I Only: Recommended Phase II Dose of Tosedostat	The recommended phase 2 dose (RP2D) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle. If 0 or 1 of 6 patients in Dose Level 1 experience DLT during the first cycle, Dose Level 1 will be presumed to be the RP2D.; DLTs are followed through completion of the first cycle.	Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)
Primary	Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLTs)	Possibly/probably/definitely related to study treatment in 1st cycle (cyc); *Grade (Gr) 4 neutropenia >7 day, Febrile neutropenia of any duration with temperature = 38.5 °C, Gr 4 anemia requires transfusion therapy on more than 2 occasions in 7 days, Gr 4 thrombocytopenia; Possibly/probably/definitely related gr. 3/4 non-hematologic toxicity that occurs 1st cyc with the following EXCEPTIONS: Gr 3 nausea/vomiting/diarrhea/anorexia <72 hours that returns to Gr 1 prior to the start of cyc 2, Gr 3 hand-foot syndrome will only be considered a DLT for patients who have received 1 week of supportive care treatment with no improvement, Gr 3 fatigue that returns to Gr 1 prior to the start of cyc 2, Gr 3 flu-like symptoms <72 hours that returns to Gr 1 prior to start of cyc 2, Gr 3 arthralgia or myalgias <72 hours that return to Gr 1 prior to the start of cyc 2, Gr 3 potassium/phosphorus/magnesium that is asymptomatic or of non-clinical significance <72 hours, Gr 3 hypoalbuminemia	Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)
Primary	Progression-free Survival (PFS) Rate	PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.; Progressive disease (PD); Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).; Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.	3 months
Secondary	Overall Response Rate (ORR)	ORR = Complete response + partial response; Target lesions; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.; Non target lesions *Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).	Up to 18 months
Secondary	Time-to-progression (TTP)	-Progressive disease (PD); Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).; Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase	Up to 24 months
Secondary	Overall Survival Rate (OS)		Up to 1 year from completion of treatment (median treatment length 81.50 days (28.00-346.00)
Secondary	Number of Participants With a CA19-9 Response	CA19-9 is a tumor marker that is used in the management of pancreatic cancer. Rising CA19-9 levels may mean the tumor is growing and decreasing CA19-9 levels may mean the tumor is shrinking or the amount of cancer in the body is decreasing; A CA19-9 response means that the tumor marker has decreased over baseline (before treatment started) levels	Completion of treatment (median treatment length 81.50 days (28.00-346.00)

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine